A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Status:
Recruiting
Trial end date:
2026-01-20
Target enrollment:
Participant gender:
Summary
This study is being done to learn about etavopivat, a once a day medicine taken by mouth in
adolescents with sickle cell disease. The main goals are to study safety and how long
etavopivat stays in the bloodstream, while also studying if there are benefits from taking
etavopivat. Eligible participants who enter the study will start a 96-week treatment period.
At the end of the 96 weeks, participants will have an end of study visit that occurs 4 weeks
later. The participants will receive etavopivat every day throughout the treatment period.